{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-GD2+3F8+Monoclonal+Antibody", "query": { "intervention": "Anti-GD2 3F8 Monoclonal Antibody" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-GD2+3F8+Monoclonal+Antibody&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-07T01:32:05.802Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01857934", "title": "Therapy for Children With Advanced Stage Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "topotecan", "type": "DRUG" }, { "name": "hu14.18K322A", "type": "BIOLOGICAL" }, { "name": "peripheral blood stem cell harvest", "type": "PROCEDURE" }, { "name": "surgical resection", "type": "PROCEDURE" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "BIOLOGICAL" }, { "name": "natural killer cell infusion", "type": "BIOLOGICAL" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "GM-CSF", "type": "BIOLOGICAL" }, { "name": "G-CSF", "type": "BIOLOGICAL" }, { "name": "mesna", "type": "DRUG" }, { "name": "levetiracetam", "type": "DRUG" }, { "name": "interleukin-2", "type": "BIOLOGICAL" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "CliniMACS", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "RADIATION", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 153, "start_date": "2013-07-05", "completion_date": "2025-12-31", "has_results": true, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-07T01:32:05.802Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01857934" }, { "nct_id": "NCT00002560", "title": "Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "monoclonal antibody 3F8", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 40, "start_date": "1994-02", "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2013-06-28", "last_synced_at": "2026-10-07T01:32:05.802Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002560" }, { "nct_id": "NCT00743496", "title": "A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Melanoma", "Osteosarcoma", "Ewing Sarcoma" ], "interventions": [ { "name": "Anti-GD2 antibody", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 50, "start_date": "2008-10-08", "completion_date": "2014-04-18", "has_results": false, "last_update_posted_date": "2017-08-17", "last_synced_at": "2026-10-07T01:32:05.802Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00743496" }, { "nct_id": "NCT00037011", "title": "Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "beta-glucan", "type": "BIOLOGICAL" }, { "name": "monoclonal antibody 3F8", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "49 Years", "sex": "ALL", "summary": "Up to 49 Years" }, "enrollment_count": null, "start_date": "2001-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-18", "last_synced_at": "2026-10-07T01:32:05.802Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00037011" }, { "nct_id": "NCT01419834", "title": "Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Humanized 3F8 Monoclonal Antibody (Hu3F8)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 68, "start_date": "2011-08-15", "completion_date": "2023-08-02", "has_results": false, "last_update_posted_date": "2023-08-04", "last_synced_at": "2026-10-07T01:32:05.802Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01419834" }, { "nct_id": "NCT00450307", "title": "Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "monoclonal antibody 3F8", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 32, "start_date": "2005-06", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2013-10-16", "last_synced_at": "2026-10-07T01:32:05.802Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450307" }, { "nct_id": "NCT00004110", "title": "Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "monoclonal antibody 3F8", "type": "BIOLOGICAL" }, { "name": "etoposide", "type": "DRUG" }, { "name": "isotretinoin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-31", "last_synced_at": "2026-10-07T01:32:05.802Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004110" }, { "nct_id": "NCT02502786", "title": "Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Osteosarcoma" ], "interventions": [ { "name": "humanized anti-GD2 antibody", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Months", "maximum_age": "40 Years", "sex": "ALL", "summary": "13 Months to 40 Years" }, "enrollment_count": 46, "start_date": "2015-07", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-07T01:32:05.802Z", "location_count": 3, "location_summary": "Los Angeles, California • New York, New York • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02502786" }, { "nct_id": "NCT02130869", "title": "A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Lymphoma", "High-risk Tumor" ], "interventions": [ { "name": "CD133+ selected autologous stem cell infusion", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "hu14.18K322A", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "GM-CSF", "type": "BIOLOGICAL" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Haploidentical natural killer cell infusion", "type": "DEVICE" }, { "name": "G-CSF", "type": "BIOLOGICAL" }, { "name": "Etoposide phosphate", "type": "DRUG" }, { "name": "CliniMACS", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 8, "start_date": "2014-10-10", "completion_date": "2017-12-20", "has_results": false, "last_update_posted_date": "2017-12-22", "last_synced_at": "2026-10-07T01:32:05.802Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02130869" }, { "nct_id": "NCT00002458", "title": "Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "monoclonal antibody 3F8", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": null, "start_date": "1987-11", "completion_date": "2001-09", "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-10-07T01:32:05.802Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002458" } ] }